MedTrace Logo

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-05-14

No results posted yet for this study

Summary

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

BMF-219

BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Sponsors & Collaborators

  • Biomea Fusion Inc.

    lead INDUSTRY

Principal Investigators

  • Juan Pablo Frias, MD · Biomea Fusion Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-28
Primary Completion
2025-05-20
Completion
2025-07-18
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06152042 on ClinicalTrials.gov